Skip to main content

Advertisement

SpringerLink
Log in

Abnormal Expression of PFDN4 in Colorectal Cancer: A Novel Marker for Prognosis

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Prefoldin 4 (PFDN4) is a transcriptional factor that regulates the cell cycle. PFDN4 is upregulated in breast tumor and breast cancer cell lines, but its significance in colorectal cancer (CRC) is not fully understood.

Methods

The present study assessed 129 patients who underwent surgery for CRC and assessed three cell lines derived from human CRC. The correlation of gene expression with clinical parameters in patients was assessed by knockdown experiments with these cell lines.

Results

Patients with high PFDN4 expression had a statistically relatively better prognosis, and those with low PFDN4 expression showed poorer overall survival than those with high expression. The assessment of PFDN4 knockdown in the three cell lines demonstrated that the siRNA inhibition resulted in a statistically significant increase in cell growth and invasiveness.

Conclusions

The data strongly suggest that PFDN4 expression is a prognostic factor in CRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.

    Article  PubMed  Google Scholar 

  2. Jones OM, John SK, Horseman N, et al. Cause and place of death in patients dying with colorectal cancer. Colorectal Dis. 2007;9:253–7.

    Article  CAS  PubMed  Google Scholar 

  3. Kohno SI, Luo C, Nawa A, et al. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther. 2007;14:918–26.

    Article  CAS  PubMed  Google Scholar 

  4. Yamasaki M, Takemasa I, Komori T, et al. The gene expression profile represents the molecular nature of liver metastasis in colorectal cancer. Int J Oncol. 2007;30:129–38.

    CAS  PubMed  Google Scholar 

  5. Aliaga JC, Deschenes C, Beaulieu JF, et al. Requirement of the MAP kinase cascade for cell cycle progression and differentiation of human intestinal cells. Am J Physiol. 1999;277(3 Pt 1):G631–41.

    CAS  PubMed  Google Scholar 

  6. Yamatodani T, Ekblad L, Kjellen E, et al. Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol. 2009;135:395–402.

    Article  CAS  PubMed  Google Scholar 

  7. Collins C, Volik S, Kowbel D, et al. Comprehensive genome sequence analysis of a breast cancer amplicon. Genome Res. 2001;11:1034–42.

    Article  CAS  PubMed  Google Scholar 

  8. Vainberg IE, Lewis SA, Rommelaere H, et al. Prefoldin, a chaperone that delivers unfolded proteins to cytosolic chaperonin. Cell. 1998;93:863–73.

    Article  CAS  PubMed  Google Scholar 

  9. Japanese Society for Cancer of the Colon and Rectum. Guidelines for therapy of colorectal cancer (in Japanese). Tokyo: Kanehara Shuppan; 2005.

  10. Sobin LH, Witedkind CH. International Union Against Cancer (UICC). TNM classification of malignant tumors. 5th ed. New York: Wiley-Liss; 1997. p. 66–9.

  11. Christensen TG, Burke B, Dexter DL, Zamcheck N. Ultrastructural evidence of dimethylformamide-induced differentiation of cultured human colon carcinoma cells. Increased expression of desmosomes. Cancer. 1985;56:1559–65.

    Article  CAS  PubMed  Google Scholar 

  12. Ishizu K, Sunose N, Yamazaki K, et al. Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. Biol Pharm Bull. 2007;30:1779–83.

    Article  CAS  PubMed  Google Scholar 

  13. Aznavoorian S, Liotta LA, Kupchik HZ. Characteristics of invasive and noninvasive human colorectal adenocarcinoma cells. J Natl Cancer Inst. 1990;82:1485–92.

    Article  CAS  PubMed  Google Scholar 

  14. Mimori K, Mori M, Shiraishi T, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer. 1997;76:531–6.

    CAS  PubMed  Google Scholar 

  15. Mori M, Staniunas RJ, Barnard GF, et al. The significance of carbonic anhydrase expression in human colorectal cancer. Gastroenterology. 1993;105:820–6.

    CAS  PubMed  Google Scholar 

  16. Tsujino T, Seshimo I, Yamamoto H, et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res. 2007;13:2082–90.

    Article  CAS  PubMed  Google Scholar 

  17. Lagers AM, Sier CF, Hawinkels LJ, et al. MMP-2 geno-phenotype is prognostic factor for colorectal cancer survival, whereas MMP-9 is not. Br J Cancer. 2008;98:1820–3.

    Article  Google Scholar 

  18. Iijima M, Kano Y, Nohno T, Namba M. Cloning of cDNA with possible transcription factor activity at the G1-S phase transition in human fibroblast cell lines. Acta Med Okayama. 1996;50:73–7.

    CAS  PubMed  Google Scholar 

  19. Hansen WJ, Cowan NJ, Welch WJ. Prefoldin-nascent chain complexes in the folding of cytoskeletal proteins. J Cell Biol. 1999;145:265–77.

    Article  CAS  PubMed  Google Scholar 

  20. Hodgson G, Hager JH, Volik S, et al. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet. 2001;29:459–64.

    Article  CAS  PubMed  Google Scholar 

  21. Andre T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 2007;25:3732–8.

    Article  CAS  PubMed  Google Scholar 

  22. Wolpin BM. Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134:1296–310.

    Article  CAS  PubMed  Google Scholar 

  23. Kornmann M, Formentini A, Ette C, et al. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol. 2008;34:1316–21.

    CAS  PubMed  Google Scholar 

  24. Bathe OF, Dowden S, Sutherland F, et al. Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer. 2004;4:32.

    Article  PubMed  Google Scholar 

  25. Lacy AM, Garcia-Valdecasas JC, Delgado S, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet. 2002;359:2224–9.

    Article  PubMed  Google Scholar 

  26. Weeks JC, Nelson H, Gelber S, et al. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA. 2002;287:321–8.

    Article  PubMed  Google Scholar 

  27. Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004;350:2050–9.

    Article  Google Scholar 

  28. Jayne DG, Guillou PJ, Thorpe H, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007;25:3061–8.

    Article  PubMed  Google Scholar 

  29. Koshariya M, Jagad RB, Kawamoto J, et al. An update and our experience with metastatic liver disease. Hepatogastroenterology. 2007;54:2232–9.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

    Norikatsu Miyoshi MD, Hideshi Ishii MD, Masayoshi Tokuoka MD, Hirofumi Akita MD, Mitsugu Sekimoto MD, Yuichiro Doki MD, PhD & Masaki Mori MD, PhD, FACS

  2. Department of Molecular and Cellular Biology, Division of Molecular and Surgical Oncology, Medical Institute of Bioregulation, Kyushu University, Ohita, Japan

    Hideshi Ishii MD, Koshi Mimori MD & Naohiro Nishida MD

Authors
  1. Norikatsu Miyoshi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideshi Ishii MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koshi Mimori MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naohiro Nishida MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masayoshi Tokuoka MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hirofumi Akita MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mitsugu Sekimoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuichiro Doki MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masaki Mori MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaki Mori MD, PhD, FACS.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 2798 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miyoshi, N., Ishii, H., Mimori, K. et al. Abnormal Expression of PFDN4 in Colorectal Cancer: A Novel Marker for Prognosis. Ann Surg Oncol 17, 3030–3036 (2010). https://doi.org/10.1245/s10434-010-1138-5

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-010-1138-5

Keywords

Search

Navigation